BR112022013979A2 - Derivados de carboxamida heteroaromáticos como inibidores da calicreína plasmática - Google Patents
Derivados de carboxamida heteroaromáticos como inibidores da calicreína plasmáticaInfo
- Publication number
- BR112022013979A2 BR112022013979A2 BR112022013979A BR112022013979A BR112022013979A2 BR 112022013979 A2 BR112022013979 A2 BR 112022013979A2 BR 112022013979 A BR112022013979 A BR 112022013979A BR 112022013979 A BR112022013979 A BR 112022013979A BR 112022013979 A2 BR112022013979 A2 BR 112022013979A2
- Authority
- BR
- Brazil
- Prior art keywords
- plasmakalkrein
- inhibitors
- carboxamide derivatives
- heteroaromatic
- heteroaromatic carboxamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157259 | 2020-02-13 | ||
| PCT/EP2021/053286 WO2021160718A1 (en) | 2020-02-13 | 2021-02-11 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022013979A2 true BR112022013979A2 (pt) | 2022-10-11 |
Family
ID=69591572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022013979A BR112022013979A2 (pt) | 2020-02-13 | 2021-02-11 | Derivados de carboxamida heteroaromáticos como inibidores da calicreína plasmática |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11760745B2 (https=) |
| EP (1) | EP4103562A1 (https=) |
| JP (3) | JP7230277B2 (https=) |
| KR (1) | KR20220141333A (https=) |
| CN (2) | CN115052873A (https=) |
| AR (2) | AR121341A1 (https=) |
| AU (1) | AU2021218952A1 (https=) |
| BR (1) | BR112022013979A2 (https=) |
| CA (1) | CA3168690A1 (https=) |
| CL (2) | CL2022002101A1 (https=) |
| CO (1) | CO2022011254A2 (https=) |
| CR (2) | CR20250167A (https=) |
| DO (2) | DOP2022000157A (https=) |
| EC (1) | ECSP22062410A (https=) |
| IL (2) | IL320007A (https=) |
| JO (1) | JOP20220186A1 (https=) |
| MX (3) | MX2022009941A (https=) |
| PE (2) | PE20221591A1 (https=) |
| SA (1) | SA522440127B1 (https=) |
| TW (2) | TWI873290B (https=) |
| WO (1) | WO2021160718A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839711A (zh) | 2018-10-10 | 2021-05-25 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的苯基四唑衍生物 |
| TW202144331A (zh) * | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TWI873290B (zh) * | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| WO2025001956A1 (zh) * | 2023-06-30 | 2025-01-02 | 远森制药（杭州）有限公司 | 杂芳族甲酰胺类化合物及其在医药上的应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| DE10207037A1 (de) | 2002-02-20 | 2003-08-28 | Bayer Cropscience Gmbh | 2-Amino-4-bicyclyamino-6H-1,3.5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| DE10230012A1 (de) * | 2002-07-04 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 5,6-Dihydro-4H-imidazo[4,5,1-ij]chinoline,ihre Herstellung und ihre Verwendung als Arzneimittel |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2005089362A (ja) | 2003-09-17 | 2005-04-07 | Sumitomo Chemical Co Ltd | アリールピラゾリン化合物及びその用途 |
| EP2259679A4 (en) | 2008-01-31 | 2011-09-14 | Joslin Diabetes Ct | METHODS OF TREATING KALLIKREIN RELATED DISORDERS |
| ES2674745T3 (es) * | 2010-02-11 | 2018-07-03 | Bristol-Myers Squibb Company | Macrociclos como inhibidores del factor XIa |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| US20140378474A1 (en) | 2012-01-27 | 2014-12-25 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| MY174018A (en) | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
| WO2017001926A2 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc | Therapeutic inhibitory compounds |
| JP6855477B2 (ja) | 2015-10-27 | 2021-04-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害薬としてのヘテロアリールカルボキサミド誘導体 |
| WO2017072020A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| CN110022875A (zh) | 2016-07-11 | 2019-07-16 | 莱福斯希医药公司 | 治疗性抑制化合物 |
| JP7175914B2 (ja) | 2017-04-21 | 2022-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血漿カリクレイン阻害剤としてのヘテロアリールカルボキサミド誘導体 |
| JP7064512B2 (ja) * | 2017-05-17 | 2022-05-10 | デナリ セラピューティクス インコーポレイテッド | キナーゼ阻害剤およびその使用 |
| US10695334B2 (en) | 2018-08-16 | 2020-06-30 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| EP4031547B1 (en) | 2019-09-18 | 2024-07-17 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof |
| TWI873290B (zh) | 2020-02-13 | 2025-02-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
-
2021
- 2021-02-09 TW TW110104875A patent/TWI873290B/zh active
- 2021-02-09 TW TW114103224A patent/TW202535863A/zh unknown
- 2021-02-11 JP JP2022514811A patent/JP7230277B2/ja active Active
- 2021-02-11 JO JOP/2022/0186A patent/JOP20220186A1/ar unknown
- 2021-02-11 IL IL320007A patent/IL320007A/en unknown
- 2021-02-11 PE PE2022001696A patent/PE20221591A1/es unknown
- 2021-02-11 CA CA3168690A patent/CA3168690A1/en active Pending
- 2021-02-11 CR CR20250167A patent/CR20250167A/es unknown
- 2021-02-11 KR KR1020227031639A patent/KR20220141333A/ko active Pending
- 2021-02-11 MX MX2022009941A patent/MX2022009941A/es unknown
- 2021-02-11 CR CR20220382A patent/CR20220382A/es unknown
- 2021-02-11 BR BR112022013979A patent/BR112022013979A2/pt unknown
- 2021-02-11 CN CN202180011395.3A patent/CN115052873A/zh active Pending
- 2021-02-11 CN CN202310088017.6A patent/CN116120287B/zh active Active
- 2021-02-11 AU AU2021218952A patent/AU2021218952A1/en active Pending
- 2021-02-11 WO PCT/EP2021/053286 patent/WO2021160718A1/en not_active Ceased
- 2021-02-11 IL IL295125A patent/IL295125B2/en unknown
- 2021-02-11 EP EP21706489.8A patent/EP4103562A1/en active Pending
- 2021-02-11 US US17/173,213 patent/US11760745B2/en active Active
- 2021-02-11 PE PE2023001617A patent/PE20231985A1/es unknown
- 2021-02-12 AR ARP210100385A patent/AR121341A1/es unknown
-
2022
- 2022-08-03 DO DO2022000157A patent/DOP2022000157A/es unknown
- 2022-08-04 CL CL2022002101A patent/CL2022002101A1/es unknown
- 2022-08-10 EC ECSENADI202262410A patent/ECSP22062410A/es unknown
- 2022-08-10 CO CONC2022/0011254A patent/CO2022011254A2/es unknown
- 2022-08-11 SA SA522440127A patent/SA522440127B1/ar unknown
- 2022-08-12 MX MX2025013436A patent/MX2025013436A/es unknown
- 2022-08-12 MX MX2025013435A patent/MX2025013435A/es unknown
-
2023
- 2023-02-15 JP JP2023021625A patent/JP7703587B2/ja active Active
- 2023-04-28 CL CL2023001244A patent/CL2023001244A1/es unknown
- 2023-08-25 US US18/455,865 patent/US12479827B2/en active Active
- 2023-09-14 DO DO2023000195A patent/DOP2023000195A/es unknown
- 2023-09-18 US US18/468,885 patent/US20240076286A1/en active Pending
- 2023-11-17 AR ARP230103113A patent/AR131110A2/es unknown
-
2025
- 2025-06-25 JP JP2025107413A patent/JP2025148369A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022013979A2 (pt) | Derivados de carboxamida heteroaromáticos como inibidores da calicreína plasmática | |
| JOP20180099B1 (ar) | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي | |
| MX380276B (es) | Inhibidor jak. | |
| BR112022001067A2 (pt) | Inibidores duplos de atm e dna-pk para uso em terapia antitumoral | |
| CY1126110T1 (el) | Παραγωγα βενζοϋδροξαμικου οξεος ως εκλεκτικοι αναστολε1σ του hdac6 | |
| CL2023001369A1 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112014008495A2 (pt) | inibidores de proteína quinase | |
| BR112015025413A2 (pt) | inibidores de proteína cinase | |
| MX368504B (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| BR112016006651A8 (pt) | derivados de quinolizina substituídos, composição farmacêutica que os compreede e uso dos mesmos. | |
| BR112016015983A2 (pt) | Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica | |
| BR112012017402A2 (pt) | inibidores de vírus de flaviviridae | |
| BR112013018601A2 (pt) | composto, uso de composto, composição farmacêutica, e, produto farmacêutico | |
| MX360857B (es) | Régimen de dosificación para inhibidores de janus quinasa (jak). | |
| BR112017009647A2 (pt) | 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer | |
| BR112015020350A2 (pt) | derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd | |
| MD20140044A2 (ro) | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare | |
| BR112019020421A8 (pt) | Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres | |
| BR112019024322A2 (pt) | Compostos e composições terapêuticos e métodos de uso dos mesmos | |
| BR112015027629A2 (pt) | Inibidores de nicotinamido fosforribosiltransferase, composições, produtos e seus usos | |
| BR112019003320A2 (pt) | compostos de heteroaril carboxamida como inibidores de ripk2 | |
| BR112015021768A2 (pt) | inibidores do vírus da hepatite c | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| BR112022017725A2 (pt) | Composto 67a inibidor de rad51 (2301085-06-1) em uma dosagem específica para o tratamento de câncer | |
| BR112023022298A2 (pt) | Moduladores de trex1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022024809-8 PROTOCOLO 870220112892 EM 05/12/2022 11:59. |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025021106-0 PROTOCOLO 870250088800 EM 30/09/2025 17:50. |